Metacare Co., Ltd.

As of June 30, 2026, Metacare Co., Ltd. carries a market capitalization of 20.66B, placing it among publicly traded companies globally. Its enterprise value stands at 95.65B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Metacare Co., Ltd. has 17.18M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.52, and the price-to-book ratio stands at 0.16.

As of June 30, 2026, Metacare Co., Ltd. trades at an EV/EBITDA multiple of 21.90 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.39 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 70.92 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 95.65B versus a market cap of 20.66B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Metacare Co., Ltd. maintains a current ratio of 0.48, meaning it holds 0.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 53.72, indicating elevated leverage, while an interest coverage ratio of 1.58 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Metacare Co., Ltd. posted a negative return on equity (ROE) of -1.29, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -0.75, reflecting losses generated across the asset base. The company generates approximately 1.37B in revenue per employee across its workforce of 29.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 57.47 indicates how many times Metacare Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Metacare Co., Ltd. recorded an income tax benefit of -69.94M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -1.91B and -1.59B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, Metacare Co., Ltd.'s stock has declined approximately 95.53% over the past 52 weeks. The 50-day moving average sits at 1,285.72, while the 200-day moving average is 13,108.50.

Over the twelve months ended June 30, 2026, Metacare Co., Ltd. generated 39.95B in revenue and converted that into -1.59B in net income, yielding earnings per share of -105.83. EBITDA reached 4.37B, while operating income came in at 1.35B.

As of June 30, 2026, Metacare Co., Ltd. holds 11.24B in cash and equivalents against 73.97B in total debt, resulting in a net debt position of 60.87B. Total book value stands at 125.42B, with working capital of -52.88B providing operational flexibility.

Metacare Co., Ltd. produced 3.74B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -382.45M in capital expenditures, free cash flow totaled 3.35B - equivalent to 192.96 per share.

Over the twelve months ended June 30, 2026, Metacare Co., Ltd. posted a gross margin of 26.96, reflecting its pricing power and cost economics. The operating margin of 3.38 and net profit margin of -3.99 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 16.04, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -75.43, meaning Metacare Co., Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Metacare Co., Ltd.'s most recent stock split took place on May 18, 2026 with a 10:1 split ratio.

As of June 30, 2026, Metacare Co., Ltd. has an Altman Z-Score of -0.04, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.